drugset / Trial / NCT00573157

The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis

NCT00573157

Phase 2/3 Terminated 6 enrolled EMD Serono ZymoGenetics · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to learn whether atacicept treatment leads to improvement in kidney function in subjects with active lupus nephritis in combination with mycophenolate mofetil (MMF) and corticosteroids. The study was sponsored by Merck Serono International; operational oversight was provided by ZymoGenetics.

Timeline

Start
2007-12
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Atacicept Protein / enzyme biologic 150 mg Subcutaneous
Background Mycophenolate Mofetil Small molecule 1500 mg Oral
Background Prednisone Other / unclassified 7.5 mg
Background Prednisone Other / unclassified 10 mg

Indications